CA2934462A1 - Compositions and methods of treating ocular diseases - Google Patents

Compositions and methods of treating ocular diseases Download PDF

Info

Publication number
CA2934462A1
CA2934462A1 CA2934462A CA2934462A CA2934462A1 CA 2934462 A1 CA2934462 A1 CA 2934462A1 CA 2934462 A CA2934462 A CA 2934462A CA 2934462 A CA2934462 A CA 2934462A CA 2934462 A1 CA2934462 A1 CA 2934462A1
Authority
CA
Canada
Prior art keywords
antibody
antigen binding
binding fragment
subject
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2934462A
Other languages
English (en)
French (fr)
Inventor
Rekha Bansal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelmed Therapeutics Inc
Original Assignee
Novelmed Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelmed Therapeutics Inc filed Critical Novelmed Therapeutics Inc
Publication of CA2934462A1 publication Critical patent/CA2934462A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2934462A 2013-12-24 2014-08-06 Compositions and methods of treating ocular diseases Abandoned CA2934462A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920541P 2013-12-24 2013-12-24
US61/920,541 2013-12-24
PCT/US2014/049938 WO2015099838A2 (en) 2013-12-24 2014-08-06 Compositions and methods of treating ocular diseases

Publications (1)

Publication Number Publication Date
CA2934462A1 true CA2934462A1 (en) 2015-07-02

Family

ID=53479755

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934462A Abandoned CA2934462A1 (en) 2013-12-24 2014-08-06 Compositions and methods of treating ocular diseases

Country Status (6)

Country Link
US (2) US10183989B2 (https=)
EP (1) EP3086809A4 (https=)
JP (1) JP2017502023A (https=)
AU (1) AU2014370404A1 (https=)
CA (1) CA2934462A1 (https=)
WO (1) WO2015099838A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
US11020686B2 (en) * 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
WO2019033081A1 (en) * 2017-08-11 2019-02-14 Massachusetts Eye And Ear Infirmary INHIBITION OF THE SUPPLEMENTARY ALTERNA PATHWAY FOR THE TREATMENT OF RETINAL ISCHEMIC LESION AND GLAUCOMA
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
JP7477457B2 (ja) 2018-04-03 2024-05-01 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
CN109999015A (zh) * 2019-04-24 2019-07-12 江苏省中医药研究院 紫草素在制备预防或治疗房颤药物中的用途
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
AU2021356298A1 (en) * 2020-10-07 2023-05-04 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511576A (ja) * 2001-11-09 2005-04-28 アイテック・ファーマシューティカルズ 眼球血管新生病を治療する方法
EP1931379B1 (en) * 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
NZ571791A (en) 2006-03-08 2012-03-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
US20100015139A1 (en) * 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
US9745367B2 (en) * 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
RU2473563C2 (ru) * 2007-06-07 2013-01-27 Дженентек, Инк. АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
CA2811221C (en) * 2010-03-10 2018-01-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
CA2869477C (en) 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor c3 antibodies and uses thereof
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US9243070B2 (en) * 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof

Also Published As

Publication number Publication date
WO2015099838A2 (en) 2015-07-02
US10696740B2 (en) 2020-06-30
AU2014370404A1 (en) 2016-07-07
JP2017502023A (ja) 2017-01-19
EP3086809A4 (en) 2017-11-29
US10183989B2 (en) 2019-01-22
US20190169279A1 (en) 2019-06-06
EP3086809A2 (en) 2016-11-02
WO2015099838A3 (en) 2015-10-29
US20160319002A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
US10696740B2 (en) Methods of treating ocular diseases
JP6462750B2 (ja) 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
TWI449535B (zh) 針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途
JP7107914B2 (ja) ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
IL240898A (en) Anti-c5a antibodies for manufacture of medicaments for treating complement-associated disorders
MX2014004449A (es) Tratamiento de enfermedad ocular.
CA2700481A1 (en) Antigen binding proteins
KR20200138290A (ko) C3-결합제 및 이의 사용 방법
US20180371082A1 (en) Novel antibody useful in neurological or neurodegenerative disorders
CN113166237A (zh) 抗fam19a5抗体的用途
KR20230146053A (ko) 보체 c3 항원 결합 단백질
KR20220007128A (ko) 항-ｓｅｍａ３ａ 항체 및 눈 또는 안구 질환 치료를 위한 이의 용도
TW202246351A (zh) Htra1結合劑及其使用方法
US12540187B2 (en) Method of treating vascular eye and retinal diseases by administration of anti-Neuropilin 1A antibodies
CN110381999B (zh) 结合人cd160的化合物及其用途
AU2021304993B2 (en) Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof
EA049293B1 (ru) АНТИ-Nrp1A АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ГЛАЗ ИЛИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ
TW202530256A (zh) 多特異性抗原結合多肽之組合物及使用方法

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200831